FDA's Long-Term Safety Net: Emphasizing the Critical Role of Extension Studies in Drug Approvals

A recent analysis published in JAMA highlights the indispensable role of extension studies in the FDA's regulatory process, serving as a long-term safety net for new treatments. These studies are crucial for assessing the sustained durability of treatment benefits and detecting rare or delayed adverse events that may not manifest within the shorter observation windows of pivotal trials. The findings underscore the importance for sponsors to integrate extension studies as designed protocol phases rather than optional add-ons.